Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah ...

Kymriah, the first chimeric antigen receptor T cell (CAR-T) therapy approved in Canada is now available at certified sites in Quebec to treat certain patients with relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL; Quebec"